Diabetes Prevention Drugs Will Be Addressed In FDA Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
Metabolic syndrome may also be discussed in draft document expected to be out by year-end.
You may also be interested in...
Galvus Trial May Show Potential For Modifying Type 2 Diabetes Treatment Guidelines
Novartis initiates 7,500-patient head-to-head trial investigating the DPP-IV inhibitor compared to thiazolidinediones.
Galvus Trial May Show Potential For Modifying Type 2 Diabetes Treatment Guidelines
Novartis initiates 7,500-patient head-to-head trial investigating the DPP-IV inhibitor compared to thiazolidinediones.
FDA Preventative Drugs Guidance Will Address Trial Design, Biomarkers
Agency will host a workshop with DIA in the spring to explore new scientific strategies for developing preventative therapies, FDA's Gottlieb says.